VIR

VIR-7831 (GSK4182136) | COMET-ICE

COVID-19

Phase 2/3 (Data)

Exp Date

Q4 2020

Amp Volatility Score

Catalyst Info & Data Links

TITLE: VIR-7831 in COVID - Phase 2/3 (Data)

  • ClinicalTrial.gov (NCT04545060): VIR-7831 for the Early Treatment of COVID-19 in Outpatients (COMET-ICE)


WHAT IS THE CATALYST EVENT?


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • End of the Year 2020


PRIOR DATA

PRESS RELEASES

MECHANISM OF ACTION / RATIONALE

  • VIR-7831 is a monoclonal antibody that has demonstrated the ability to neutralize SARS-CoV-2 live virus in vitro. The antibody binds to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1 (also known as SARS), indicating that the epitope is highly conserved, which may make it more difficult for escape mutants to develop. VIR-7831 has been engineered to enhance bioavailability and have an extended half-life.

Updated by HC

#VIR, #VIR-7831, #COVID, #GSK, #Antibody

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon